Skip to content
-
Sativex for the management of multiple sclerosis symptoms (PubMed)
-
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (PubMed)
-
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (PubMed)
-
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors (PubMed)
-
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial (PubMed)
-
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis(PubMed)
-
Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis(PubMed)
-
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis (PubMed)
-
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain(PubMed)
-
Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (PubMed)
-
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis (European Journal of Neurology)
-
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors (ScienceDirect)
-
Cannabinoid Modulation of Neuroinflammatory Disorders (Current Neuropharmacology)
-
Cannabinoids and multiple sclerosis (Pharmacology and Therapeutics)
-
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial (The Lancet)
-
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up (J Neurol Neurosurg Psychiatry)
-
Cannabinoids in the management of spasticity associated with multiple sclerosis (Neuropsychiatric Disease and Treatment)
-
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study (Multiple Sclerosis Journal)
-
Interaction Between The Protective Effects Of Cannabidiol And Palmitoylethanolamide In Experimental Model Of Multiple Sclerosis In C57BL/6 Mice (Neuroscience)
-
The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis (MedScape)
-
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review (BioMed Central)
